GBP2 and neoplasm: Furthermore, anti-PD-1 treatment resulted in a tumor inhibition rate of about 43.7%, whereas depletion of GBP2 only caused about 16.9% tumor inhibition rate, indicating a potential role of GBP2 in the responsiveness to PD-1 blockade (figure 7G, H).